论文部分内容阅读
目的探讨血清中sB7-H3和NSE对肺癌的应用价值。方法采收集68例肺癌患者、75例肺部良性病和65例健康对照者的血清,分别检测sB7-H3和NSE,统计诊断效能,分析sB7-H3和NSE与TMN分期的关系。结果肺癌组的sB7-H3和NSE阳性率显著高于肺部良性病组和健康对照组(P<0.05),而肺部良性病组和健康对照组差异无统计学意义(P>0.05)。sB7-H3诊断肺癌患者的敏感度(61.76%)高于NSE(51.47%)(P<0.05),sB7-H3特异度(92.86%)与NSE(94.29%)相当(P>0.05)。两项串联检测时特异性略升至97.86%,并联检测时敏感度显著提高到79.69%。sB7-H3和NSE随着TMN分期增加而升高,除了sB7-H3的Ⅰ/Ⅱ期和Ⅲ期无差别,其余均有差异。结论sB7-H3和NSE对肺癌具有较强的诊断效能,尤其sB7-H3在早期诊断中具有十分重要意义,两项并联检测能有效避免一些漏检病例。
Objective To investigate the clinical value of serum sB7-H3 and NSE in lung cancer. Methods Sera from 68 patients with lung cancer, 75 patients with benign lung disease and 65 healthy controls were collected for detection of sB7-H3 and NSE. The diagnostic efficacy of sB7-H3 and NSE was analyzed. The relationship between sB7-H3, NSE and TMN stage was analyzed. Results The positive rate of sB7-H3 and NSE in lung cancer group was significantly higher than that in benign lung disease group and healthy control group (P <0.05), but there was no significant difference between benign lung disease group and healthy control group (P> 0.05). The sensitivity of sB7-H3 in diagnosing lung cancer patients was 61.76% higher than that of NSE patients (51.47%) (P <0.05). The sB7-H3 specificity (92.86%) was comparable to that of NSE patients (94.29%). The specificity of the two in-line assays slightly increased to 97.86% and the sensitivity in parallel assays increased significantly to 79.69%. The levels of sB7-H3 and NSE increased with the increase of TMN staging, with the exception of stage I / II and stage III of sB7-H3. Conclusion sB7-H3 and NSE have strong diagnostic efficacy for lung cancer, especially sB7-H3 in the early diagnosis is of great significance, two parallel detection can effectively avoid some missed cases.